Last quote by Michael Nawrath
A positive result of the study would have been welcome to add a little pep to waning Lucentis sales. For the small company Ophthotech this will be much worse than for Novartis, but it's still a negative result.
Dec 12 2016
We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which Michael Nawrath is associated, including Novartis, Actelion, and result. Most recently, Michael Nawrath has been quoted saying: “Actelion's shares have risen 400 percent based on the strength of the PAH portfolio alone.” in the article Actelion's ambitious independent-minded CEO will drive up takeover price. An other article where Michael Nawrath has been quoted is Roche advances skin cancer trials as part of combination therapy strategy | Reuters.
Quotes by Michael Nawrath
Nov 28 2016
Actelion's shares have risen 400 percent based on the strength of the PAH portfolio alone.
Nov 07 2016
Even when the data they are presenting was taken from a sample of only a few patients, the efficacy without the use of any chemotherapy is certainly extraordinarily high.
Oct 01 2016
These court cases are simply the last resort of original drug makers to wring a few more months or a year of exclusivity from their blockbusters.